Down 20%: Another Dendreon Earnings Disaster
Sales increased for the quarter 8% to $73 million, but unfortunately that came in at the low end of the guidance. And that growth is after the first quarter's disastrous $68 million performance. Losses decreased to $0.45 sequentially, but the company acknowledged that it won't hit its guidance target for year-over-year annual growth and refused to give additional guidance.
In this video, health-care analyst David Williamson discusses these results and key conference-call takeaways for investors in Dendreon, why they should be concerned about increasing competition, and why time is not on their side.
Still in the dark about how Obamacare might affect you and your portfolio? Don't worry -- you're not alone. To help prepare investors for the massive changes coming to the American health-care system, The Motley Fool created a special free report that makes this complex topic easily understandable. Download "Everything You Need to Know About Obamacare" and discover how the law may affect your taxes, health insurance, and investments. Click here for your free copy today.
The article Down 20%: Another Dendreon Earnings Disaster originally appeared on Fool.com.David Williamson owns shares of Johnson & Johnson. Follow David on Twitter: @MotleyDavid. The Motley Fool recommends Exelixis and Johnson & Johnson and owns shares of Dendreon, Exelixis, and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.